An Iffy Future For Alkermes After Failed Trials

Alkermes efforts to create its own line of wholly-owned products beyond its side business as a formulation expert have not been the most successful so far. In fact, data released Jan. 21 could sideline one of its most promising efforts.

The biotech announced results from closely-watched Phase III trials of major depressive disorder therapy ALKS-5461. Both the FORWARD-3 trial and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category